Recent cases of avian influenza H5N1 and the swine-origin 2009 H1N1 have caused a great concern that a global disaster like the 1918 influenza pandemic may occur again. Viral transmission begins with a critical interaction between hemagglutinin (HA) glycoprotein, which is on the viral coat of influenza, and sialic acid (SA) containing glycans, which are on the host cell surface. To elucidate the role of HA glycosylation in this important interaction, various defined HA glycoforms were prepared, and their binding affinity and specificity were studied by using a synthetic SA microarray. Truncation of the N-glycan structures on HA increased SA binding affinities while decreasing specificity toward disparate SA ligands. The contribution of each monosaccharide and sulfate group within SA ligand structures to HA binding energy was quantitatively dissected. It was found that the sulfate group adds nearly 100-fold (2.04 kcal/mol) in binding energy to fully glycosylated HA, and so does the biantennary glycan to the monoglycosylated HA glycoform. Antibodies raised against HA protein bearing only a single N-linked GlcNAc at each glycosylation site showed better binding affinity and neutralization activity against influenza subtypes than the fully glycosylated HAs elicited. Thus, removal of structurally nonessential glycans on viral surface glycoproteins may be a very effective and general approach for vaccine design against influenza and other human viruses.
T
he highly pathogenic H5N1 and the 2009 swine-origin influenza A (H1N1) viruses have caused global outbreaks and raised a great concern that further changes in the viruses may occur to bring about a deadly pandemic (1, 2) . Important contributions to our understanding of influenza infections have come from the studies on hemagglutinin (HA), a viral coat glycoprotein that binds to specific sialylated glycan receptors in the respiratory tract, allowing the virus to enter the cell (3) (4) (5) (6) . To cross the species barrier and infect the human population, avian HA must change its receptorbinding preference from a terminally sialylated glycan that contains ␣2,3 (avian)-linked to ␣2,6 (human)-linked sialic acid motifs (7) , and this switch could occur through only two mutations, as in the 1918 pandemic (8) . Understanding the factors that affect influenza binding to glycan receptors is thus critical for developing methods to control any future crossover influenza strains that have pandemic potential.
HA is a homotrimeric transmembrane protein with an ectodomain composed of a globular head and a stem region (3) . Both regions carry N-linked oligosaccharides (9) , which affect the functional properties of HA (10, 11) . Among different subtypes of influenza A viruses, there is extensive variation in the glycosylation sites of the head region, whereas the stem oligosaccharides are more conserved and required for fusion activity (11) . Glycans near antigenic peptide epitopes interfere with antibody recognition (12) , and glycans near the proteolytic activation site of HA modulate cleavage and influence the infectivity of influenza virus (13) . Mutational deletion of HA glycosylation sites can affect viral receptor binding (14) . Our analysis of HA sequences revealed that the peptide sequences around the glycosylation sites are highly conserved (Fig. S1 ), which suggests a central functional significance for HA glycosylation; however, little is known regarding how the structure and composition of its glycans affect HA activity, including structure, receptor binding, and immune response.
Results

Creating Defined HA Glycoforms for Quantitative Glycan Microarray
Profiling. The glycan microarray is a powerful tool for investigating carbohydrate-protein interactions (15) (16) (17) (18) and provides a new platform for influenza virus subtyping (16) (17) (18) . Although powerful, understanding HA-glycan interactions by array analysis has been complicated by two issues. First, HA binding specificity is affected by the spatial arrangement and composition of the arrayed glycans and the binding detection method used (19) . Second, the changes in the peptide sequence at or near glycosylation sites may alter HA's 3D structure, and thus receptor-binding specificity and affinity. Indeed, HAs from different H5N1 subtypes have different glycan-binding patterns (18) . Mutagenesis of glycosylation sites on H1 and H3 has been studied in the whole-viral system (16, 20) . However, it is not known how changes in glycosylation affect receptor-binding specificity and affinity, especially with regard to the most pathogenic H5N1 HA. To address this question, we have developed a glycan microarray comprising extensive structural analogs of the HA-binding ligand, and several defined glycoforms of HA were prepared by using the H5 consensus sequence (21) for quantitative binding analysis. Although previous studies have used HA from insect cell expression (16) , glycosylation in insect cells differs from mammalian cells, with a marked difference being that complex type N-glycans terminating in galactose and sialic acid are not produced in insect cells. To generate native fully glycosylated HA variants (HA fg ), human embryonic kidney (HEK293) cells were used. To generate high-mannose-type glycosylation (HA hm ), HEK293S cells, which are deficient in N-acetylglucosaminyltransferase I (GnTI Ϫ ), were used. To further address the effect of HA glycan structure on HA receptorbinding affinity and specificity, sugar residues were enzymatically removed from the expressed HAs. Sialic acid residues were removed from HA fg by neuraminidase (NA) treatment to pro-duce desialylated HA (HA ds ). Endoglycosidase H (Endo H) was used to truncate all of the glycan structures down to a single GlcNAc residue to produce monoglycosylated HA (HA mg ). Thus, a total of four glycoform variants of HA were generated ( Fig. 1 and Fig. S2 ), and the glycan structures are verified by mass spectral analysis (Figs. S3 and S4 and Table S1 ). Circular dichroism of the variants confirmed that their secondary structures are similar (Fig. 1 A) . It is noted that an attempt to express functional HA in Escherichia coli failed because of the lack of glycosylation.
The synthetic sialic acid glycan array consisted of 17 of the ␣2,3 (glycans 1-17) and 7 of the ␣2,6 (glycans 21-27) sialosides designed to explore the glycan specificity of influenza viruses (see Fig. 3 ). The synthetic sialosides with a five-carbon linker terminated with amine were prepared and covalently attached onto NHS-coated glass slides by forming an amide bond under aqueous conditions at room temperature. The printing procedure was based on the standard microarray robotic printing technology, as reported previously (15, 22) . We applied the HA variants to the sialic acid slides and then hybridized them with primary antibody, followed by detection with a secondary antibody conjugated to Cy3. This analysis indicated that the H5N1 HA consensus sequence specifically binds to ␣2,3 sialosides but not ␣2,6 sialosides ( Fig. 2A ), in accordance with previous studies (16, 18) . To our surprise, the binding strength with ␣2,3 sialosides grew successively stronger from HA fg , HA ds , and HA hm , to HA mg (Fig. 2 A) by qualitative binding via relative fluorescence intensity.
We next prepared a quantitative array to determine surface dissociation constants (17) . To avoid any skewing by antibody layering, HA was directly labeled with the fluorescent dye Cy3 (19) . Direct binding assays were performed by serial dilution of Cy3-labeled HAs to establish the relative binding intensities. The dissociation constants on the surface were determined by plotting the HA concentrations against fluorescence intensity for each of the 24 sialosides printed on the glass slide. The dissociation constant K D,surf values were calculated based on the Langmuir isotherms (see Fig. 2B and Fig. S5 ). The monovalent HA-sialoside binding is weak, exhibiting dissociation constants in the millimolar range (K D ϭ 2.5 ϫ 10 Ϫ3 M) (23); however, HA is involved in multivalent interactions with sialosides on the host cell surface, which can be seen in the quantitative array profiling ( Table 1 ).
All HA glycoforms showed strong binding to receptor glycans with a sulfate group at the 6 position of the third GlcNAc residue from the nonreducing end (glycans 4 and 7). This sulfate group is important for binding to H5 HA (16, 18) . In addition, it was observed that glycan 4 is the best ligand for HA fg , whereas glycans 13-15 are better ligands than glycan 6 for HA mg , indicating a possible multivalent interaction within the ligand-binding site, or the exposure of more receptor-binding domains to bigger biantennary sialosides (glycans 13 and 14) . Interestingly, HA binding substantially increases as its N-glycan structures become less complex (Fig. 2B) Values for ⌬G multi represent a quantitative measurement of stabilizing energy from HA-glycan interactions. A successive decrease in ⌬G multi correlated with the systematic decrease in complexity/ truncation of the N-glycan structures on HA ( Table 1 ). The differences in free energy change (⌬⌬G) between HA variants are caused by unique glycan structures (Table S2) , and the largest difference is between HA fg and HA mg (⌬⌬G HA fg 3 HA mg ; see Table S2 ), which is consistent with the largest difference in binding energy resulting from trimming off most of the N-glycan down to a single GlcNAc. It is noted that values of ⌬⌬G are similar except for glycans 4 and 7 (Table S2 ), indicating that glycans on HA do not significantly affect the binding affinity with sulfated ␣2,3 trisaccharide (16) .
The molecular details of the HA-receptor binding (i.e., the contribution from each structural component comprising a glycan receptor) can be addressed by comparing the differences in free energy change (⌬⌬G values) between different receptor sialosides ( Fig. 3 and Table S3 ). Dissecting the energy contribution of the receptor sialosides responsible for HA binding will reveal key points of specificity that can be used to design new HA inhibitors. Sialosides ␣2,3 linked to galactose residues with ␤1,4 (Gal␤1-4) linkages possess better binding affinity than those with Gal␤1-3 linkages (18) . This is reflected in the comparison of the Neu5Ac-␣2,3-galactose (Neu5Ac␣2,3Gal) disaccharide backbone (Fig. 3A,  glycan 1, red box highlight) , where trisaccharides 3 and 6 only differ in the linkage between Gal and GlcNAc. Here, the ⌬⌬G (1 3 3) for all HA variants is negative (stabilizing HA-receptor interaction), whereas the ⌬⌬G(1 3 6) for all HA variants is positive (destabilizing HA-receptor interaction; Fig. 3A and Table S3 ). This observation indicates that Neu5Ac␣2,3Gal␤1-4Glc/GlcNAc is the core glycan component interacting with the HA-binding pocket. Moreover, the value of ⌬⌬G(1 3 9) for all HA variants is positive, indicating a negative perturbation caused by the ␤6-linked mannose at the third position (Fig. 3A and Table S3 ). Thus, binding energy is affected by inner sugar residues and their linkage patterns to the distal Neu5Ac␣2,3Gal disaccharide ligand (Fig. 3A) . This analysis shows that a GlcNAc residue at the third position is favored for all HA variants. However, in comparing ⌬⌬G values for glycans 13 and 14 ( Fig. 3E and Table S3 ) to glycan 6, multivalent interactions in the binding site with the biantennary sialoside are apparent, and for HA mg , this intramolecular avidity is more significant for driving binding than the structural effect exerted by the third sugar.
Next, we compared receptor glycans 10, 11, 12, and 15, which have the same basic core structure (glycan 8 trisaccharide) but differ by elongation (glycans 11 and 12) or addition of an ␣2,6 sialic acid at the third position (glycan 15; Fig. 3B ). It is interesting that the sialoside with the branched ␣2,6 sialic acid greatly increased HA avidity, whereas the longer ␣2,3 sialoside extending from glycan 8 resulted in a weaker binding by HAs [⌬⌬G (8 3 15) Ͼ ⌬⌬G (8 3 11) ϳ ⌬⌬G (8 3 10) Ͼ ⌬⌬G (8 3 12) ; Fig. 3B and Table S3 ].
Glycans 3-5 snd 6-7 share the same trisaccharide backbone but differ by the addition of a sulfate group (glycan 4) or fucose residue (glycan 5) on the third GlcNAc from the nonreducing end. The sulfate group can stabilize the HA-receptor glycan interaction up to 2.044 kcal/mol [⌬⌬G (6 3 7) ], the largest energy gap between two receptor sialosides. Among all of the HA variants, the fully glycosylated variant showed the most significant differences in free energy changes, with values of ⌬⌬G(3 3 4) HA fg (Ϫ1.653 kcal/mol) and ⌬⌬G(6 3 7) HA fg (Ϫ2.044 kcal/mol), and the size of the free energy gain lessened as the glycan structure became more simplified; i.e., HA fg Ͼ HA ds Ͼ HA hm Ͼ HA mg . Thus, sulfated glycans dramatically enhance HA binding, and fully glycosylated HA maximizes this effect (Fig. 3 C and D) , which may be important for H5N1 pathogenesis. On the other hand, the fucosylated receptor analogs greatly destabilize HA binding, with all glycosylated HA variants showing a positive ⌬⌬G(3 3 5) (Fig. 3C) . These large differences in ⌬⌬G(3 3 4) and ⌬⌬G(3 3 5) are likely caused by an important binding interaction in the receptor-binding pocket, which the sulfate group maximizes and the fucose sterically blocks. The weak binding of HA fg is unlikely due to the competition of its sialylglycans, because removal of sialic acid has a small effect on binding, and HA fg still exhibits a strong affinity for certain specific sialylglycans.
Vaccine Design Using Monoglycosylated HA. The monoglycosylated hemagglutinin HA mg described in this work shows a similar secondary structure and better binding affinity to host receptors compared with its fully glycosylated counterpart. Our recent study also indicated that a single GlcNAc residue to Asn is the minimum component of the N-glycan required for glycoprotein folding and stabilization (24) . Because proteins are superior immunogens to glycans, the monoglycosylated HA was tested as a protein vaccine against influenza viruses. Antisera from HA fg and HA mg immunizations were compared with regard to their ability to bind native HAs and to neutralize H5 viruses (Fig. 4) . Indeed, in contrast to HA fg , the antiserum from HA mg showed stronger neutralization of the virus. The HA mg antiserum also binds to H1 (New Caledonia/ 1999) in addition to the H5 subtypes Vietnam/1194, H5 (Anhui), and H5 (ID5/2005) (Fig. S6) . Notably, the HA mg vaccine was much more protective than the HA fg vaccine in a challenge study (Fig.  4C) . The amino acid sequences of H1, H3, and H5 isolated from humans since 1918 were compared (Fig. S1 ). The overall sequence identity was about 65% between H1 and H5, and about 40% between H3 and H5. In addition, the glycosylation sites and the underlying peptide sequences between H1 and H5 were more conserved compared with those between H3 and H5.
Discussion
This study shows that the systematic simplification of N-glycans on HA results in a successive increase in binding to ␣2,3 sialosides but not to ␣2,6 sialosides. To our knowledge, this is a previously undescribed study to show the effect of HA's outer and inner glycans on receptor binding and to quantitatively dissect the binding affinity and energetic contributions of HA-receptor interactions.
HA glycosylation affects the function of influenza HA (25). Interestingly, as the level of glycosylation on influenza H3N2 has increased since 1968, the morbidity, mortality, and viral lung titers have decreased (26) . Our finding that HA with a single GlcNAc attached to the glycosylation sites showed relaxed specificity but enhanced affinity to ␣2,3 sialosides suggests that the N-glycans on HA may cause steric hindrance near the HA-receptor binding domain. The high specificity for receptor sialosides may prevent the virus from binding to some other specific glycans on the human lung epithelial cell surface. On the other hand, HA with truncated glycans can recognize ␣2,3 receptor sialosides with higher binding affinity and less specificity, suggesting that reducing the length of glycans on HA may increase the risk of avian flu infection. It is, however, unclear how the changes of HA-receptor interaction via glycosylation affect the infectivity of the virus and the NA activity in the viral life cycle.
HA with a single GlcNAc is a promising candidate for influenza vaccine because such a construct retains the intact structure of HA and can be easily prepared (e.g., via yeast). It also can expose conserved epitopes hidden by large glycans to elicit an immune response that recognizes HA variants in higher titer. This strategy opens a new direction for vaccine design and, together with other different vaccine strategies (27) (28) (29) (30) and recent discoveries of HAneutralizing antibodies (31) (32) (33) (34) (35) (36) , should facilitate the development of vaccines against viruses such as influenza, hepatitis C virus, and HIV.
Materials and Methods
Protein Expression and Purification. The plasmid that encodes the secreted HA was transfected into the human embryonic kidney cell lines of either HEK293EBNA (ATCC number CRL-10852) or the GnTI Ϫ HEK293S cells (37) by using polyethyleneimine and was cultured in Freestyle 293 expression medium (Invitrogen) supplemented with 0.5% bovine calf serum. The supernatant was collected 72 h after transfection and cleared by centrifugation. HA proteins were purified with Nickel-chelation chromatography as previously described (38) to obtain fully glycosylated HA fg and high-mannose-type HAhm. To obtain the HA protein without sialylation-the desialylated HA ds-the purified protein was treated with 20 mM Clostridium NA (Sigma) for 2 h at 37°C. After the NA treatment, the protein was purified again to be separated from the NA. The purified HA hm was treated with Endo H (NEB) for 2 h at 37°C to produce HA protein with a single GlcNAc at the glycosylation sites, the monoglycosylated HA mg.
Glycan Microarray Fabrication. Twenty-four sialic acid-containing glycans designed for HAs were prepared chemically and used for array fabrication. Microarrays were printed (BioDot; Cartesian Technologies) by robotic pin (SMP3; TeleChem International) deposition of Ϸ0.7 nL of various concentrations of amine-containing glycans in printing buffer (300 mM phosphate buffer, pH 8.5, containing 0.005% Tween 20) from a 384-well plate onto NHS-coated glass slides (Nexterion H slide; SCHOTT North America). The slides for sialosides were spotted with solutions of glycans 1-17 and 21-27 with concentrations of 100 M in each row for one glycan from bottom to top, with 12 replicates horizontally placed in each subarray, and each slide was designed for 16 grids for further incubation experiments. Printed slides were allowed to react in an atmosphere of 80% humidity for an hour followed by desiccation overnight, and they were stored at room temperature in a desiccator until use. Before the binding assay, these slides were blocked with ethanolamine (50 mM ethanolamine in borate buffer, pH 9.2) and then washed with water and PBS buffer, pH 7.4, twice.
Indirect Binding Assay. HA glycosylated variants were prepared in 0.005% Tween 20/PBS buffer, pH 7.4, and added to cover the grid on glycan array with application of a coverslip. After incubation in a humidified chamber with shaking for 1 h, the slides were washed three times with 0.005% Tween 20/PBS buffer, pH 7.4. Next, rabbit anti-H5N1 HA antibody was added to the slides and incubated in a humidified chamber for 1 h. After washing the slides with 0.005% Tween 20/PBS buffer three times, Cy3-conjugated goat anti-rabbit IgG antibody was added to the slides and incubated in a humidified chamber for another 1 h. The slides were washed three times with 0.05% Tween 20/PBS buffer, pH 7.4; three times with PBS buffer, pH 7.4; and three times with H 2O, and then dried. The slides were scanned at 595 nm (for Cy3) with a microarray fluorescence chip reader (GenePix Pro 6.0; Molecular Devices).
Direct Binding Assay. Cy3-labeled HA proteins with different glycosylations were prepared in 0.005% Tween 20/PBS buffer, pH 7.4, and added to cover the grid on glycan array with application of a coverslip. After incubation in a humidified chamber with shaking for 1 h, the slides were washed three times with 0.005% Tween 20/PBS buffer, pH 7.4; three times with PBS buffer, pH 7.4; and three times with H 2O, and then dried. The slides were scanned at 595 nm (for Cy3) with a microarray fluorescence chip reader (GenePix Pro 6.0; Molecular Devices). Mice, Vaccination, and Challenge. Female 6-to 8-week-old BALB/c mice (n ϭ 15) were immunized intramuscularly with 20 g of purified HAfg or HAmg proteins in 50 L of PBS, pH 7.4, and mixed with 50 L of 1 mg/mL aluminum hydroxide (Alum; Sigma) at weeks 0 and 2. Blood was collected 14 days after immunization, and serum samples were collected from each mouse. The immunized mice were challenged intranasally with a genetically modified H5N1 virus, NIBRG-14, with a lethal dose (100-fold lethal dose to 50% of mice). The mice were monitored daily for 14 days after the challenge for survival. All animal experiments were evaluated and approved by the Institutional Animal Care and Use Committee of Academia Sinica.
Microneutralization
